Reviewed Mar 2026 | PubMed sources
Active Market
France is selected. The evidence comparison is still valid, but provider availability, legal positioning, and cost assumptions may still be staged for later rollout.

Sermorelin vs Hexarelin: Head-to-Head Comparison

Sermorelin is a GHRH analog with former FDA approval and a physiological release pattern, while hexarelin is the most potent GHRP but carries rapid desensitization risk. Sermorelin is better suited for long-term protocols, while hexarelin may be useful for short-term intensive GH release.

Approved Comparison Routing

Approved options in this comparison

A
Sermorelin

Sermorelin is currently modeled on this site as an approved treatment path for: Diagnosis and treatment of growth hormone deficiency in children. Brand names in the current dataset: Geref.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It does not replace checking current labeling, payer rules, or local prescribing conditions.

Want to discuss Sermorelin with a provider?

Sermorelin is currently modeled on this site as an approved treatment path. Use the provider matcher to narrow fit by state, insurance, budget, and urgency.

Join provider rollout

Side-by-Side Comparison

DimensionSermorelinHexarelin
Evidence LevelFormerly FDA-approved; decades of dataExtensive clinical data including cardiac studies
FDA StatusPreviously FDA-approvedNot approved
MechanismGHRH receptor agonistGhrelin receptor agonist (most potent GHRP)
GH Release PotencyModerate, physiologicalVery high; strongest GHRP
Desensitization RiskLow; suitable for long-term useHigh; rapid tachyphylaxis
Side EffectsFlushing, headache, mild injection painCortisol/prolactin elevation, water retention
Unique BenefitsPhysiological GH release, well-characterized safetyCardioprotective effects in heart failure patients
Evidence Level
Sermorelin
Formerly FDA-approved; decades of data
Hexarelin
Extensive clinical data including cardiac studies
FDA Status
Sermorelin
Previously FDA-approved
Hexarelin
Not approved
Mechanism
Sermorelin
GHRH receptor agonist
Hexarelin
Ghrelin receptor agonist (most potent GHRP)
GH Release Potency
Sermorelin
Moderate, physiological
Hexarelin
Very high; strongest GHRP
Desensitization Risk
Sermorelin
Low; suitable for long-term use
Hexarelin
High; rapid tachyphylaxis
Side Effects
Sermorelin
Flushing, headache, mild injection pain
Hexarelin
Cortisol/prolactin elevation, water retention
Unique Benefits
Sermorelin
Physiological GH release, well-characterized safety
Hexarelin
Cardioprotective effects in heart failure patients

Peptide Overviews

Sermorelin

AFDA Approved

Sermorelin is the shortest fully functional fragment of GHRH (amino acids 1-29). It was the first GHRH analog approved by the FDA, marketed as Geref for diagnostic and therapeutic use. Geref was subsequently discontinued in the U.S. market, though sermorelin remains available through compounding pharmacies. Geref was subsequently discontinued in the U.S. market, though sermorelin remains available through compounding pharmacies.

Growth Hormone SecretagoguesFDA Approved
View full Sermorelin profile →

Hexarelin

BHuman Studies

Hexarelin is one of the most potent synthetic GH secretagogues. Research also suggests it has direct cardioprotective effects independent of its GH-releasing properties.

Growth Hormone SecretagoguesNot Approved
View full Hexarelin profile →

GLP-1 Support Essentials

Products that can support side-effect management, hydration, and protein intake.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Supplies for Both

Common research handling and preparation supplies for injectable peptide workflows.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Sermorelin vs Hexarelin: FAQ